Streptozotocin and high-fat diet-treated animal models are used to induce a combination of cognitive impairments, amyloid and Tau pathology, neuroinflammation, oxidative stress, impaired insulin signaling, and vascular changes, which are factors that have been implicated in the development of AD [23]. Here, MAPT is linked to Cognitive impairment.